Press releases
STC-15, the first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies.
Read more
Presentations will showcase the activity of first-in-class METTL3 inhibitors in a range of solid tumours, building on prior POC data in AML. Establishes new therapeutic opportunities for METTL3 inhibitors across a wide range of solid cancers
Read more
Dr. Holz has over 25 years’ experience in pharmaceutical drug development in Europe and North America.
Read more
Dr. Lauder has over 15 years of business development experience working with biotech and pharmaceutical companies, and academia.
Read more
The paper entitled ‘Role of RNA modifications in cancer’ is an authoritative and comprehensive review of the emerging and highly promising field of RNA epigenetics, highlighting pathways implicated in cancer to-date, describing their biological functions and their connections to the disease.
Read more